Expression and clinical diagnostic value of miR-383 in patients with severe preeclampsia

Ting Li**, Bing Zhou**, Yijing He¹, Jue Liu¹, Yun Li²

¹Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Nanhua University, Hengyang 421001, China
²Department of brain function and neuroelectricity science, Affiliated Nanhua Hospital, University of South China, Hengyang 421002, China

*Correspondence to: un82fg@163.com
Received February 28, 2020; Accepted May 17, 2020; Published June 5, 2020
Doi: http://dx.doi.org/10.14715/cmb/2020.66.3.14
Copyright: © 2020 by the C.M.B. Association. All rights reserved.

Abstract: This study aimed to investigate the expression and clinical diagnostic value of miR-383 in patients with severe preeclampsia. Thirty patients with severe preeclampsia from July 2017 to December 2018 were selected as a research group, twenty healthy pregnant women undergoing physical examination at the same period were selected as a control group, and miR-383 and miR-16 in placenta tissue of the two groups were detected by qRT-PCR. ROC curve was drawn to evaluate the predictive value of diagnostic efficiency, Spearman test was used for correlation analysis, and Logistic univariate and multivariate analysis was performed on the risk factors related to the metastasis of severe preeclampsia. The miR-383 expression in the research group was significantly lower than that in the control group (P< 0.001), while the miR-16 expression in the research group was significantly higher than that in the control group (P< 0.001). The miR-383 and miR-16 expression levels were tied to TNM staging and metastasis (P< 0.001). The sensitivity, specificity and AUC of miR-383 single diagnosis were 75.00%, 83.33% and 0.847 respectively, and those of miR-16 single diagnosis were 65.00%, 63.33% and 0.728 respectively. The relative expression of miR-383 in placenta tissue was negatively correlated with APACHE II score of severe preeclampsia (r = -0.4129, P= 0.0233), but the relative expression of miR-16 in placenta tissue was positively correlated with APACHE II score of severe preeclampsia (r = 0.9833, P< 0.001). Blood pressure, miR-383, miR-16 at the admission of pregnant women were independent risk factors for severe preeclampsia. miR-383 and miR-16 might participate in the process of occurrence, development and metastasis of severe preeclampsia, and could be used as potential biomarkers of placental tissue for its diagnosis and disease assessment of metastasis.

Key words: miR-383; Severe preeclampsia; Clinical diagnosis; miR-16; APACHE II score.

Introduction

Preeclampsia is a kind of pregnancy disease with great harm. With the increase of gestational weeks of patients, pregnant women and fetuses bear more and more harm (1, 2). Although the morbidity of severe preeclampsia is relatively low, it has increased by 2% year by year (3). According to the disease severity of pregnant women, preeclampsia can be divided into mild and severe ones. Inadequate vascular remodeling of the placenta bed and systemic vascular endothelial injury are all the causes leading to adverse pregnancy outcomes in preeclampsia patients. Severe preeclampsia is often accompanied by impairment of the functions of important organs of the heart, brain and kidney, which seriously threatens the health of mothers and infants. At the same time, it places great health and economic burden on the family of pregnant women. In order to reduce the harm of severe preeclampsia, attention should be paid to the monitoring of early pregnancy or early preeclampsia (4, 5). Measurement of early blood pressure and albuminuria detection are the conventional detection indicators for preeclampsia patients in clinical practice (6, 7), but the initial cause of severe preeclampsia is still unclear. With the continuous development of molecular biology, medical researchers began to analyze the pathogenesis of human severe preeclampsia from the direction of gene biology of the disease. However, inhibiting the progress of severe preeclampsia is an important part of the current study (8).

The current research showed that MicroRNAs (miRNAs) were an endogenous non-coding single-stranded RNA with gene expression regulation function (9, 10), and it inhibits or promotes diseases in different diseases, and it abnormally expresses in severe preeclampsia. However, miRNAs with different expression levels detected in different studies are different (11). At present, there is a lack of research on the expression and predictive value of miR-383 and miR-16 in severe preeclampsia metastasis. However, it has been reported that the miR-16 expression is up-regulated in severe preeclampsia cells, and its appropriate down-regulation can inhibit the progression of severe preeclampsia (12). On the contrary, miR-383 has been proved to be far less expressed in colorectal cancer, medulloblastoma and other tumor tissues than in normal tissues. Up-regulating the miR-383 expression can inhibit the proliferation of colon cancer cells and reduce the invasion and migration (13). We speculated that miR-383 and miR-16 were related to the progression of preeclampsia. Therefore, in order to provide a new theoretical basis for the diagnosis and treatment of se-
vere preeclampsia in molecular biology, the expression characteristics and clinical significance of miR-383 and miR-16 were studied.

Materials and Methods

Data collection
Thirty patients with severe preeclampsia treated in The Second Affiliated Hospital of Nanhua University from July 2017 to December 2018 were selected as the research group, and 20 healthy pregnant women who underwent physical examination during the same period were selected as the control group. They were (25.45±3.03) and (25.27±3.19) years old on average. Inclusion criteria: All the patients were in accordance with the diagnosis guidelines of the expert committee of severe preeclampsia; all of them were primiparas, with 29-41 weeks of gestation; they were conscious (14); they had normal liver and kidney function and no other malignant tumors. Exclusion criteria: All patients who received chemotherapy, immunotherapy and radiotherapy before surgery were excluded. The research was approved by the Ethics Committee of the Second Affiliated Hospital of Nanhua University, patients and their families were informed in advance, and they signed informed consent forms.

Main reagents, instruments and detection methods

Main reagents and instruments
Main reagents and instruments were as follows: Trizol reagent (Applied Invitrogen, U.S.), qRT-PCR kit and miniScript reverse transcription kit (Dalian TaKaRa company), HBS-1096A enzyme label analyzer (Nanjing Detic Experimental Equipment Co., Ltd.), real-time quantitative PCR instrument (BioRad company, U.S.), and primer sequences of miR-383 and miR-16 as well as internal reference U6 and miRNA negative control were synthesized and designed by Shanghai GenePharma Company (Table 1).

Detection of miR-383 and miR-16
The expression levels of miR-383 and miR-16 of placenta tissue in the two groups were detected by qRT-PCR. Total RNA of placental tissue was extracted according to Trizol reagent operation instructions and dissolved in 20 μL DEPC water, and it was then reverse-transcribed using a reverse transcription kit. The reaction system was as follows: M-MLV 1 μl, Oligo (dT) 1 μl, RNA enzyme inhibitor 0.5 μl, d NTPs 1 μl, RNase free water 15 μl. After that, it was incubated 60 min at 38 °C. We took 1 μl c DNA and put it at 85 °C for 5 s, and we used the synthesized c DNA as a template for qRT-PCR amplification. The PCR reaction system was prepared: 10×PCR buffer 2.5 μl, d NTPs 1 μl, upstream and downstream primers 1 μl each, Taq DNA Polymerase 0.25 μl, ddH2O supplemented to 25 μl. Reaction conditions were as follows: pre-denaturation 95 °C, 15 min, denaturation 95 °C, 15 s, annealing 60 °C, 30 s, a total of 35 cycles, an extension for 15 min at 72 °C. Each sample was provided with 3 multiple wells for 3 repeated tests, and U6 was regarded as the internal reference in miR-383 and miR-16. Afterward, the amplification curve and melting curve of Real-Time PCR were confirmed, and the relative amount of the target gene was calculated based on the result parameters. The relative quantification of the target gene was calculated by $2^{-\Delta \Delta CT}$.

Statistical methods
SPSS 17.0 software system was used for statistical analysis, the counting data were expressed by the number of cases/percentages [n(%)], and χ2 test was used for comparison between the two groups. The measurement data were expressed by mean number (X±sd), and the comparison between groups was conducted by a t-test or F test. ROC curve was drawn to select the maximum point cut-off value of the Youden index and to evaluate the predictive value of diagnostic efficiency in miR-383 and miR-16 expression in placenta tissue. Spearman test was used for correlation analysis, and Logistic univariate and multivariate analysis was performed on the risk factors related to the metastasis of moderate and severe preeclampsia in patients with severe preeclampsia. A p-value lower than 0.05 was considered statistically significant.

Results

General clinical data of patients
The age, number of pregnancies, APACHE II score, lesion site and lymph node metastasis of the research group and the control group were compared, and there was no significant difference between the two groups in terms of age, gender and other clinical general data (P>0.05) based on Table 2.

Expression levels of miR-383 and miR-16 in research group and control group
The results of qRT-PCR showed that the miR-383 expression in placenta tissue of the research group and the control group were (0.40±0.15) and (0.60±0.12) respectively, the miR-16 expression in placenta tissue of the two groups were (3.15±1.13) and (1.38±1.13) respectively. Compared with both groups, the miR-383 expression in the research group was significantly lower than that in the placenta tissue of the control group, with a statistically significant difference (P<0.001). However, the miR-16 expression in the research group was significantly higher than that in the control group (P<0.001, Figures 1A & 1B).

Relationship between the expression levels of miR-383 and miR-16 and clinicopathological characteristics of severe preeclampsia
The expression levels of miR-383 and miR-16 had
### Table 2. General clinical data of patients in current research.

| Factor                              | Research group (n=30) | Control group (n=20) | t/X² | P     |
|-------------------------------------|-----------------------|----------------------|------|-------|
| Age (years)                         |                       |                      | 0.061| 0.805 |
| ≤25                                 | 10 (33.33)            | 6 (30.00)            |      |       |
| >25                                 | 20 (66.67)            | 14 (70.00)           |      |       |
| Number of pregnancies               |                       |                      | 0.066| 0.797 |
| Multipara                           | 8 (26.67)             | 6 (30.00)            |      |       |
| Primipara                           | 22 (73.33)            | 14 (70.00)           |      |       |
| Gestational weeks of onset (week)   |                       |                      |      |       |
| ≤27                                 | 14 (46.67)            | -                    |      |       |
| >27                                 | 16 (53.33)            | -                    |      |       |
| Hemoglobin of pregnant women at admission |                   |                      | 0.000| 1.000 |
| Normal                              | 6 (20.00)             | 4 (20.00)            |      |       |
| Abnormal                            | 24 (80.00)            | 16 (80.00)           |      |       |
| Blood pressure of pregnant women at admission |             |                      | 0.178| 0.673 |
| Normal                              | 8 (26.67)             | 2 (20.00)            |      |       |
| Hypertension                        | 22 (73.33)            | 8 (80.00)            |      |       |
| Polyembryony                        | 8 (26.67)             | 3 (30.00)            | 0.042| 0.838 |
| Yes                                 | 22 (73.33)            | 7 (70.00)            |      |       |
| Blood pressure of pregnant women at the end of pregnancy |          |                      | 0.833| 0.361 |
| Normal                              | 23 (76.67)            | 9 (90.00)            |      |       |
| Hypertension                        | 7 (33.33)             | 1 (10.00)            |      |       |
| APACHE II score                     |                       |                      |      |       |
| <9                                  | 11 (36.67)            | -                    |      |       |
| 9-14                                | 9 (30.00)             | -                    |      |       |
| >14                                 | 10 (33.33)            | -                    |      |       |
nothing to do with the age of patients with severe preeclampsia, the number of pregnancies, the gestational weeks of onset, hemoglobin and polyembryony of pregnant women at admission, but was concerned with APACHE II score, blood pressure of pregnant women at admission (Table 3).

Correlation of miR-383 and miR-16 in severe preeclampsia with different APACHE II scores

The expression level of miR-383 in the placental tissue of patients with APACHE II scores < 9, 9-14 and > 14 of different severe preeclampsia were (0.50±0.13), (0.39±0.15) and (0.32±0.15), respectively. The expression level of miR-16 in the placental tissue of patients with APACHE II scores < 9, 9-14 and > 14 of different severe preeclampsia were (2.03±1.15), (3.03±1.15) and (4.25±1.15), respectively. Compared with patients with APACHE II score < 9, the relative expression levels of miR-383 and miR-16 in the placenta tissue of patients 9-14 and > 14 decreased significantly (P < 0.05). With the increase of the APACHE II score, the relative expression of miR-383 in placenta tissue decreased, while the relative expression of miR-16 in placenta tissue increased continuously. The APACHE II score of patients < 9 was set to 1, 9-14 was set to 2, and > 14 was set to 3. Spearman correlation analysis between the relative expression levels of miR-383 and miR-16 in placenta tissue and APACHE II score of different severe preeclampsia indicated that the relative expression of miR-383 in placenta tissue was negatively correlated with APACHE II score of severe preeclampsia (r = -0.4129, P = 0.0233), and the relative expression of miR-16 in placenta tissue was positively correlated with APACHE II score of severe preeclampsia (r = 0.9833, P< 0.001) based on Figures 2 A-D.

Diagnostic value of miR-383 and miR-16 in the prognosis of severe preeclampsia

In diagnosing severe preeclampsia, the sensitivity, specificity and AUC of miR-383 single diagnosis were 75.00, 83.33, and 0.847 respectively, and the sensitivity, specificity and AUC values of miR-16 single diagnosis were 65.00, 63.33, and 0.728 respectively. (Table 4, Figures 3A and 3B).

Prognostic value of miR-383 and miR-16 in patients with severe preeclampsia

Prognosis of patients with severe preeclampsia after treatment

According to the complications of patients with severe preeclampsia after treatment, they were divided into a good prognosis group and poor prognosis group.

Table 3. Relationship between the expression levels of miR-383 and miR-16 clinicopathological characteristics of severe preeclampsia.

| Group                                      | n   | miR-383       | t/F | P       | miR-16      | t/F | P       |
|--------------------------------------------|-----|---------------|-----|---------|-------------|-----|---------|
| Age (years)                                |     |               |     |         |             |     |         |
| ≤ 25                                       | 10  | 0.40±0.10     | 0.000| 0.999   | 3.10±1.14   | 0.0696| 0.945   |
| > 25                                       | 20  | 0.40±0.20     | 0.000| 0.999   | 3.13±1.10   | 0.0696| 0.945   |
| Number of pregnancies                      |     |               |     |         |             |     |         |
| Multipara                                  | 8   | 0.39±0.16     | 0.145| 0.886   | 3.14±1.14   | 0.021| 0.983   |
| Primipara                                  | 22  | 0.38±0.17     | 0.000| 0.999   | 3.15±1.13   | 0.0696| 0.945   |
| Gestational weeks of onset (week)          |     |               |     |         |             |     |         |
| ≤ 27                                       | 14  | 0.45±0.15     | 1.957| 0.060   | 2.90±1.16   | 0.618| 0.542   |
| > 27                                       | 16  | 0.35±0.13     | 0.000| 0.999   | 3.16±1.14   | 0.0696| 0.945   |
| Hemoglobin of pregnant women at admission  |     |               |     |         |             |     |         |
| Normal                                     | 6   | 0.46±0.15     | 1.899| 0.068   | 2.70±1.15   | 1.702| 0.100   |
| Abnormal                                   | 24  | 0.33±0.15     | 0.000| 0.999   | 3.60±1.16   | 0.0696| 0.945   |
| Blood pressure of pregnant women at admission|     |               |     |         |             |     |         |
| Normal                                     | 8   | 0.50±0.15     | 3.398| 0.002   | 2.80±1.16   | 2.207| 0.036   |
| Hypertension                               | 22  | 0.30±0.14     | 0.000| 0.999   | 3.85±1.15   | 0.0696| 0.945   |
| Polyembryony                               |     |               |     |         |             |     |         |
| Yes                                        | 8   | 0.40±0.16     | 0.159| 0.875   | 3.14±1.15   | 0.021| 0.983   |
| No                                         | 22  | 0.39±0.15     | 0.000| 0.999   | 3.15±1.13   | 0.0696| 0.945   |
| Blood pressure of pregnant women at the end of pregnancy | | | | | | | |
| Normal                                     | 23  | 0.48±0.14     | 2.607| 0.015   | 2.60±1.10   | 2.182| 0.038   |
| Hypertension                               | 7   | 0.32±0.15     | 4.245| 0.025   | 3.64±1.12   | 9.768| 0.001   |
| APACHE II score                            |     |               |     |         |             |     |         |
| < 9                                        | 11  | 0.50±0.13     | 0.245| 0.025   | 2.03±1.15   | 2.03±1.15 | 0.001   |
| 9-14                                       | 9   | 0.39±0.15     | 0.000| 0.999   | 3.03±1.15   | 3.03±1.15 | 0.001   |
| > 14                                       | 10  | 0.32±0.15     | 4.25±1.15 | 0.000   | 4.25±1.15   | 4.25±1.15 | 0.001   |
Compared with the two groups, the probability of postpartum complications in the good prognosis group was significantly lower than that in the poor prognosis group (P < 0.05, Table 5).

**Univariate analysis of prognosis and related factors of severe preeclampsia**

Logistic univariate analysis of risk factors related to the metastasis of moderate and severe preeclampsia in patients with severe preeclampsia showed that there were significant differences in blood, APACHE II score, miR-383, miR-16 between pregnant women with metastasis of severe preeclampsia and those without metastasis of severe preeclampsia at admission (P < 0.05). The age, lesion site, APACHE II score, miR-383, miR-16 of patients were all related to metastasis of severe preeclampsia and were risk factors for metastasis of severe preeclampsia (Tables 6 and 7).

**Multivariate analysis of metastasis of severe preeclampsia and related factors**

Risk factors related to the prognosis of severe preeclampsia were analyzed by multivariate conditional Logistic regression, and the results revealed that blood pressure, miR-383 and miR-16 at admission were independent risk factors for metastasis of severe preeclampsia (Table 8).

**Discussion**

miRNA is ubiquitous in eukaryotes and plays a role in gene regulation in cell biological processes such as cell development, differentiation and apoptosis, and the biological characteristics of different miRNA are different (15). The differential expression of miRNA in the placental tissue of preeclampsia and normal pregnant women was found in some functional studies of miRNA (16). Severe preeclampsia is an important factor leading to poor treatment effects and pregnancy outcomes of women.
Diagnostic value of miR-383 in patients with severe preeclampsia.

Preeclampsia patients. Diagnosis and treatment of patients with severe preeclampsia could reduce the risks of maternal death during pregnancy, premature delivery and neonatal death. Therefore, finding miRNA biomarkers closely related to the diagnosis and treatment of severe preeclampsia has important clinical significance (17).

In this study, we first detected the expression differences of miR-383 and miR-16 in the placenta tissue of patients with severe preeclampsia and healthy people by qRT-PCR. The results showed that the miR-383 expression in the research group was significantly lower than that in the control group and there was a statistically significant difference, while the miR-16 expression in the research group was significantly higher than that in the control group and there was a statistically significant difference. miRNA could affect the biological function of tumor cells by regulating gene expression and regulating related tumor signal pathways, thus affecting the development of tumors (18). miR-383 down-regulated in colorectal cancer, hepatocellular carcinoma and other diseases, and up-regulation of miR-383 could promote apoptosis of colorectal cancer cells (19, 20).

Researchers verified that miR-383 down-regulated the VEGFA expression and inhibited the angiogenesis of tumor endothelial cells by targeting the 3'-UTR of the VEGFA gene to inhibit its translation efficiency (21, 22). However, miR-16, as a potential target molecule for treating severe preeclampsia, was abnormally elevated in a variety of tumor tissues including severe preeclampsia. Moreover, some researches believed that miR-16 could promote the growth of placental decidua derived mesenchymal stem cells of preeclampsia patients by inhibiting miR-16 expression (23, 24). Hence, we believed that miR-383 expression down-regulated in the placenta tissue of patients with severe preeclampsia. On the contrary, miR-16 up-regulated in the placenta tissue of patients with severe preeclampsia. Then we started with the clinical data of patients in the research group to analyze the relationship between the expression levels of miR-383 and miR-16 and the clinicopathological characteristics of severe preeclampsia. Based...

**Table 5.** Diagnostic value of miR-383 and miR-16 in treatment of placenta tissue for the efficacy of PD patients.

| Indicators   | miR-383 | miR-16 |
|--------------|---------|--------|
| AUC          | 0.847   | 0.728  |
| 95% CI       | 0.7388-0.9545 | 0.5869-0.8697 |
| Std. Error   | 0.0550  | 0.0721 |
| Cut-off value| 0.493   | 2.212  |
| Sensitivity  | 75.00   | 65.00  |
| Specificity  | 83.33   | 63.33  |

**Table 6.** Incidence rate of complications.

| Group                          | The good prognosis (n=20) | Poor prognosis (n=10) | X²   | P    |
|--------------------------------|--------------------------|-----------------------|------|------|
| Pulmonary edema                | 0 (0.00)                 | 1 (10.00)             |      |      |
| Acute renal insufficiency      | 1 (5.00)                 | 2 (20.00)             |      |      |
| HELLP syndrome                 | 1 (5.00)                 | 1 (10.00)             |      |      |
| Cardiovascular and cerebrovascular accident | 0 (0.00) | 1 (10.00) |      |      |
| Total complication rate        | 2 (10.00)                | 5 (50.00)             | 5.963| 0.015|

**Table 7.** Assignment description of factors related to metastasis of severe preeclampsia.

| Correlative factor                                   | Assignment description                  |
|------------------------------------------------------|----------------------------------------|
| Age (years)                                          | < 25 =0; ≥ 25 =1                       |
| Number of pregnancies                                | Primipara =0; multipara =1              |
| Gestational weeks of onset (week)                    | ≤27=0; >27=1                           |
| Hemoglobin of pregnant women at admission            | Normal = 0; abnormal =1                |
| Blood pressure of pregnant women at admission        | Normal = 0; hypertension =1            |
| Polyembryony                                         | Yes = 0; no =1                         |
| Blood pressure of pregnant women at the end of pregnancy | Normal = 0; hypertension =1          |
| miR-383                                              | < 0.451=0; > 0.451=1                   |
| miR-16                                               | < 4.841=0; > 4.841=1                   |
| APACHE II score                                      | < 9 + 9-14=0; > 14=1                   |
on the analysis results, we speculated that the expression levels of miR-383 and miR-16 were linked to the APACHE II score of severe preeclampsia, and the blood pressure of pregnant women at admission. At present, although there is no specific study on the pathological characteristics of patients with severe preeclampsia as well as miR-383 and miR-16, there are reports on miRNAs and severe preeclampsia, which suggest that the miR-125b-1-3p expression detected by qRT-PCR shows a decreasing trend in placenta tissue of preeclampsia patients. Furthermore, the miR-125b-1-3p expression in patients with different preeclampsia severity was further detected through experiments, and we discovered that the lower its expression in placenta tissue was, the more severe state of illness was, indicating that the expression change of miRNA was tied to the clinicopathological staging of severe preeclampsia, which was similar to the results of this study, and was an excellent supplement (25).

Then, we analyzed the correlation between miR-383 and miR-16 in severe preeclampsia with different APACHE II scores and found that the relative expression of miR-383 in placenta tissue decreased with the increase of APACHE II scores, while the relative expression of miR-16 in placenta tissue increased continuously. Spearman correlation analysis signified that the relative expression of miR-383 in placenta tissue was negatively correlated with APACHE II score in severe preeclampsia, and the relative expression of miR-16 in placenta tissue was positively correlated with APACHE II score in severe preeclampsia. miRNAs were proved to be strongly linked to disease condition assessment. Through inhibiting or promoting disease development in different tumors, the expression level of miRNAs also increased or decreased significantly with disease progression (26). Finally, we analyzed the diagnostic value of miR-383 and miR-16 in metastasis of severe preeclampsia and the predictive value for metastasis of severe preeclampsia. By drawing ROC curves, we discovered that the single diagnosis of miR-383 and miR-16 had better sensitivity, specificity and AUC; in diagnosing severe preeclampsia patients, liver and kidney function, blood and urine routine, coagulation indicator and ultrasonic cardiogram and other related examinations were all routine clinical auxiliary examinations. There was a certain degree of misdiagnosis and missed diagnosis rate for metastatic severe preeclampsia in vivo, and combination with a placental tissue tumor marker could better improve the diagnostic efficiency (27, 28).

Through Logistic univariate and multivariate analysis of risk factors related to the prognosis of severe preeclampsia patients with moderate and severe preeclampsia, we confirmed that APACHE II score, blood pressure of pregnant women at admission, miR-383 and miR-16 were independent risk factors for metastasis of severe preeclampsia. However, the diagnostic efficacy and predictive value of miR-383 and miR-16 expression changes in the placenta tissue of patients with severe preeclampsia metastasis have not been studied before. In this study, miR-383 and miR-16 have certain predictive value for the diagnosis and disease prognosis in metastasis of patients with severe preeclampsia (29-44). This study confirmed the expression and predictive value of miR-383 and miR-16 in patients with severe preeclampsia, but there are some limitations. For ins-

Table 8. Univariate analysis of metastasis of severe preeclampsia and related factors.

| Factor                      | The good prognosis (n=20) | Poor prognosis (n=10) | X²   | P      |
|-----------------------------|--------------------------|-----------------------|------|--------|
| Age (years)                 |                          |                       |      |        |
| ≤25                         | 7 (35.00)                | 3 (30.00)             | 0.075| 0.784  |
| >25                         | 13 (65.00)               | 7 (70.00)             |      |        |
| Number of pregnancies       |                          |                       |      |        |
| Multipara                   | 5 (25.00)                | 3 (30.00)             | 0.085| 0.770  |
| Primipara                   | 15 (75.00)               | 7 (70.00)             |      |        |
| Gestational weeks of onset (week) | 10 (50.00)            | 4 (40.00)             | 0.268| 0.605  |
| ≤27                         | 10 (50.00)               | 6 (60.00)             |      |        |
| >27                         | 10 (50.00)               | 6 (60.00)             |      |        |
| Hemoglobin of pregnant women at admission | 4 (20.00) | 2 (20.00)             | 0.000| 1.000  |
| Normal                      | 16 (80.00)               | 8 (80.00)             | 5.455| 0.020  |
| Hypertension                | 8 (40.00)                | 0 (0.00)              |      |        |
| Polyembryony                | 12 (60.00)               | 10 (100.00)           |      |        |
| Yes                         | 6 (30.00)                | 5 (50.00)             | 1.148| 0.284  |
| No                          | 14 (70.00)               | 5 (50.00)             |      |        |
| Blood pressure of pregnant women at the end of pregnancy |     |                       | 18.260| <0.001|
| Normal                      | 20 (100.00)              | 3 (30.00)             |      |        |
| Hypertension                | 0 (0.00)                 | 7 (70.00)             |      |        |
| miR-383                     | 0.64±0.30                | 0.30±0.16             | 4.179| <0.001 |
| miR-16                      | 6.38±2.35                | 4.18±1.85             | 3.295| 0.002  |
| APACHE II score             |                          |                       |      |        |
| <9                          | 10 (50.00)               | 1 (10.00)             | 9.459| 0.009  |
| 9-14                        | 7 (35.00)                | 2 (20.00)             |      |        |
| >14                         | 3 (15.00)                | 7 (70.00)             |      |        |
tance, this study did not specifically analyze the regulatory effect of miR-383 and miR-16 expression changes on severe preeclampsia, and further explain its biological function. Besides, miR-383 and miR-16 were not analyzed with clinical routine tumor markers, which had a certain influence on the improvement of research design. Therefore, we will refer to the latest research in real-time in the later period and add corresponding research schemes to make up for design defects so as to continuously improve the research (45, 46).

In conclusion, miR-383 down-regulated in the placental tissue of patients with severe preeclampsia, while miR-16 up-regulated. miR-383 and miR-16 might participate in the process of occurrence, development and metastasis of severe preeclampsia, and could be used as potential biomarkers of placental tissue for its diagnosis and disease assessment of metastasis.

Authors' contributions
TL wrote the manuscript. BZ performed PCR. YH analyzed and interpreted the patients’ data. JL and YL helped with statistical analysis. All authors read and approved the final manuscript.

References

1. Duffy J, Thompson T, Hinton L, Salinas M, McManus RJ, Ziebland S. International Collaboration to Harmonise Outcomes in Pre-eclampsia (iHOPE) Qualitative Research Group: What outcomes should researchers select, collect and report in pre-eclampsia research? A qualitative study exploring the views of women with lived experience of pre-eclampsia. BJOG 2019; 126: 637-646.

2. Ukah UV, Magee L, Payne B, Hutcheon J, von Dadelszen P. 320. Pregnancy characteristics, management and outcomes according to different definitions of pre-eclampsia and other hypertensive disorders of pregnancy. Pregnancy Hypertens 2018; 13: S125.

3. Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, Singh M, Greco E, Wright A, Maclagan K, Poon LC. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol 2018; 51: 743-750.

4. Wimalasundera RC, Larbalestier N, Smith JH, De Ruiter A, Thom SM, Hughes AD, Poulter N, Regan L, Taylor GP. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360(9340):1152-4.

5. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol 2019; 15: 386-386.

6. Ayansina D, Black C, Hall SJ, Marks DS, van Oudenaarden A. MicroRNA control of protein expression noise. Science 2015; 348: 128-132.

7. Hill JM, Lukiw WJ. MicroRNA (miRNA)-mediated pathogenic signaling in Alzheimer’s disease (AD). Neurochem Res 2016; 41: 96-100.

8. Murphy MSQ, Tayade C, Smith GN. Maternal circulating microRNAs and pre-eclampsia: challenges for diagnostic potential. Mol Diagn Ther 2017; 21: 23-30.

9. Skalis G, Katsi V, Miliou A, Georgiopoulos G, Papazachou O, Vamvakou G, Nihoyannopoulos P, Toussoulis D, Makris T. Micro-RNAs in Preeclampsia. MicroRNA 2019; 8: 28-35.

10. Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, Poon WS, Ng HK. MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol 2013; 23: 413-425.

11. Garrido-Gomez T, Ona K, Kapidzic M, Gormley M, Simón C, Genbacev O, Fisher SJ. Severe pre-eclampsia is associated with alterations in cytotrophoblasts of the smooth chorion. Development 2017; 144: 767-777.

12. Lam JK, Chow MY, Zhang Y, Leung SW. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids 2015; 4: e252.

13. Munaut C, Tebache L, Blacher S, Noël A, Nisolle M, Chantaine F. Dysregulated circulating miRNAs in preeclampsia. Biomed Rep 2016; 5: 686-692.

14. Jiang L, Long A, Tan L, Hong M, Wu J, Cai L, Li Q. Elevated microRNA-520g in pre-eclampsia inhibits migration and invasion of trophoblasts. Placenta 2017; 51: 70-75.

15. Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov 2016; 6: 235-246.

16. Chen L, Guan H, Gu C, Cao Y, Shao J, Wang F. miR-383 inhibits its hepatocellular carcinoma cell proliferation via targeting APRIL. Tumour Biol 2016; 37: 2497-2507.

17. Fang Z, He L, Jia H, Huang Q, Chen D, Zhang Z. The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer. Iran J Basic Med Sci 2017; 20: 187.

18. Pei L, Meng S, Yu W, Wang Q, Song F, Ma L. Inhibition of microRNA-383 ameliorates injury after focal cerebral ischemia via targeting PPARγ. Cell Physiol Biochem 2016; 39: 1339-1346.

19. Wei GJ, Zheng KW, An G, Shi ZW, WangKF, Guan Y, Wang YS, Li PF, Dong DM. Comprehensive Effects of Suppression of MicroRNA-383 in Human Bone-Marrow-Derived Mesenchymal Stem Cells on Treating Spinal Cord Injury. Cell Physiol Biochem 2018; 47: 129-139.

20. Wang Y, Fan H, Zhao G, Liu D, Du L, Wang Z, Hu Y, Hou Y. miR-16 inhibits the proliferation and angiogenesis-regulating potential of mesenchymal stem cells in severe pre-eclampsia. FEBS J 2012; 279: 4510-4524.

21. Mencia Castaño I, Curtin CM and Duffy GP, O’Brien FH. Harnessing an inhibitory role of miR-16 in osteogenesis by human mesenchymal stem cells for advanced scaffold-based bone tissue engineering. Tissue Eng Part A 2019; 25: 24-33.

22. Li Q, Pan Z, Wang X, Gao Z, Ren C, Yang W. miR-125b-1-3p inhibits trophoblast cell invasion by targeting APRIL. Placenta 2018; 63: 383-386.

23. Wang Y, Fan H, Zhao G, Liu D, Du L, Wang Z, Hu Y, Hou Y. miR-16 inhibits the proliferation and angiogenesis-regulating potential of mesenchymal stem cells in severe preeclampsia. Biochem Biophys Res Commun 2014; 453: 57-63.

24. Awamleh Z, Gloor GB, Han VKM. Placental microRNAs in pregnancies with early onset intrauterine growth restriction and preeclampsia: potential impact on gene expression and pathophysiology. BMC Med Genomics 2019; 12: 91.

25. Alrahmani L, Willrich MA V. The complement alternative pathway and preeclampsia. Curr Hypertens Rep 2018; 20: 40.

26. Aziz S, Shahid R. Reversible Blindness in Severe Preeclampsia. J Soc Obstet Gynaecol Pak 2017; 7: 110-111.
29. Lou Y, Shi J, Guo D, Qureshi AK, Song L. Function of PD-L1 in antitumor immunity of glioma cells. Saudi J Biol Sci 2017; 24(4): 803-807.
30. Lou Y, Yang J, Wang L, Chen X, Xin X, Liu Y. The clinical efficacy study of treatment to Chiari malformation type I with syringomyelia under the minimally invasive surgery of resection of Submeningeal cerebellar Tonsillar Herniation and reconstruction of Cisterna magna. Saudi J Biol Sci 2019; 26(8): 1927-1931.
31. Nie Y, Luo F, Lin Q. Dietary nutrition and gut microflora: A promising target for treating diseases. Trends Food Sci Technol 2018; 75: 72-80.
32. Nie Y, Luo F, Wang L, Yang T, Shi L, Li X, Shen J, Xu W, Guo T, Lin Q. Anti-hyperlipidemic effect of rice bran polysaccharide and its potential mechanism in high-fat diet mice. Food Funct 2017; 8(11): 4028-4041.
33. Ren Y, Jiao X, Zhang L. Expression level of fibroblast growth factor 5 (FGF5) in the peripheral blood of primary hypertension and its clinical significance. Saudi J Biol Sci 2018; 25(3): 469-473.
34. Wang L, Lin Q, Yang T, Liang Y, Nie Y, Luo Y, Shen J, Fu X, Tang Y, Luo F. Oryzanol Modifies High Fat Diet-Induced Obesity, Liver Gene Expression Profile, and Inflammation Response in Mice. J Agri Food Chem 2017; 65(38): 8374-8385.
35. Zhang T, Wu X, Shaheen SM, Zhao Q, Liu X, Rinklebe J, Ren H. Ammonium nitrogen recovery from digestate by hydrothermal pretreatment followed by activated hydrochar sorption. Chem Eng J 2020; 379: 1-54.
36. Zhu B, Pang R, Chevallier J, Wei YM, Vo DT. Including intangible costs into the cost-of-illness approach: a method refinement illustrated based on the PM2.5 economic burden in China. Europ J Health Econ 2019; 20(4): 501-511.
37. Chen H, Chen Y, Yang L. Intelligent early structural health prognosis with nonlinear system identification for RFID signal analysis. Comput Commun 2020; 157: 150-161.
38. Chen HX, Huang L, Yang L, Chen YT, Huang JM. Model-based method with nonlinear ultrasonic system identification for mechanical structural health assessment. Trans Emerge Telecommun Technol 2020; 1-15.
39. Li W, Jia MX, Wang JH, Lu JL, Deng J, Tang JX, Liu, C. Association of MMP9-1562C/T and MMP13-77A/G Polymorphisms with Non-Small Cell Lung Cancer in Southern Chinese Population. Biomolecules 2019; 9(3): 107-119.
40. Liang Y, Lin Q, Huang P, Wang Y, Li J, Zhang L, Cao J. Rice Bioactive Peptide Binding with TLR4 To Overcome H2O2-Induced Injury in Human Umbilical Vein Endothelial Cells through NF-kappa B Signaling. J Agri Food Chem 2018; 66(2): 440-448.
41. Lou Y, Guo D, Zhang H, Song L. Effectiveness of mesenchymal stems cells cultured by hanging drop vs. conventional culturing on the repair of hypoxic-ischemic-damaged mouse brains, measured by stemness gene expression. Open Life Sci 2016; 11(1): 519-523.
42. Chen X, Xu Y, Meng L, Chen X, Yuan L, Cai Q, Shi W, Huang G. Non-parametric partial least squares-discriminant analysis model based on sum of ranking difference algorithm for tea grade identification using electronic tongue data. Sens Actuators B Chem 2020; 311:127924-127931.
43. Guo T, Lin Q, Li X, Nie Y, Wang L, Shi L, Xu W, Hu T, Guo T, Luo F. Octacosanol Attenuates Inflammation in Both RAW264.7 Macrophages and a Mouse Model of Colitis. J Agri Food Chem 2017; 65(18): 3647-3658.
44. Jiang X, Zhu B, Chevallier J, Xie R. Allocating provincial CO2 quotas for the Chinese national carbon program. Australian J Agri Res Econ 2018; 62(3): 457-479.
45. Yang X, Yang J, Liang X, Chen Q, Jiang S, Liu H, Gao Y, Ren Z, Yu Y, Zhong M, Yang X. Placental Editome Profiling Reveals Widespread RNA-Editing Dysregulation in Preeclampsia. bioRxiv 2019; 1:797365.
46. Traver S, Assou S, Scalici E, Haouzi D, Al-Edani T, Belloc S, Hamamah S. Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy. Hum Reprod Update 2014; 20(6): 905-23.